Solara Active Pharma Sciences Limited, has informed the exchange regarding the retirement of Mr. S. Murali Krishna from the position of the Company Secretary & Compliance Officer and Key Managerial Personnel (KMP) of the Company with effect from close of business hours of May 15, 2025

Kmp ResignedManagement Changes View source PDF Explain this filing

SOLARA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-7.9%Reaction day

₹518.04

prior close

₹518.60

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.8%-8.7% vs market

Pharmaceuticals peers, median of 150sector+0.2%-8.1% vs sector

On the reaction day the stock moved 8.7 pts less than Nifty Microcap 250 and 8.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-7.6

10m

-8.5

15m

-7.9

30m

-7.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-7.9+0.8-8.7+0.2-8.1

Next day

-8.0+2.0-10.0+1.1-9.1

-8.3+0.9-9.2+0.2-8.5

-7.3+1.7-9.0+1.0-8.4

-8.4+1.6-10.0+1.2-9.6

-7.6+2.2-9.9+0.7-8.4

-6.9+2.7-9.6+1.4-8.3

15d

-8.3+4.5-12.8+0.8-9.2

-2.4+5.6-8.0+2.2-4.6

+32.5+9.0+23.5+3.8+28.7

+17.8+3.5+14.2-1.0+18.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board of Solara Active Pharma Sciences has approved the retirement of Mr. S. Murali Krishna from the position of Company Secretary & Compliance Officer and Key Managerial Personnel with effect from close of business hours on May 15, 2025. Ms. Pooja Jaya Kumar, a qualified Company Secretary with 7 years of experience (previously at Tenshi Pharmaceuticals), has been appointed in his place effective the same date. In the same board meeting, the company approved its audited consolidated financial results for Q4 and FY25, reporting revenue from operations of Rs. 1,283.76 crores and a marginal profit after tax of Rs. 0.54 crores for the year, a significant recovery from the Rs. 566.96 crore loss in FY24 which had included large exceptional items. The board also allotted 1,00,000 equity shares under the ESOP 2018 at Rs. 252 per share, re-appointed Grant Thornton Bharat LLP as Internal Auditor, and appointed Ms. Parimala Natarajan as Secretarial Auditor for a 5-year term. The statutory auditor Deloitte Haskins & Sells LLP issued an unmodified opinion on the FY25 financial results.

Likely market impact

The Company Secretary change is routine and should not materially affect shareholders, especially since a qualified replacement has been named on the same day. The FY25 turnaround from a large loss to a small profit is encouraging, but the thin margin and continued quarterly loss in Q4 FY25 (Rs. 2.10 crore loss before tax) suggest the business recovery is still in early stages and warrants close monitoring of revenue and margin trends.